Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Date first appeared online	05/01/2020
DOI	10.1111/dom.13955
Authors	Bain S.
Journal Name	Diabetes, Obesity and Metabolism
Volume	22

Documents

• 53094.pdf , Book, Released under the terms of a Creative Commons Attribution-NonCommercial License (CC-BY-NC).